Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
89 hedge funds and large institutions have $286M invested in Inozyme Pharma in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 37 increasing their positions, 21 reducing their positions, and 11 closing their positions.
76% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 21
19% more capital invested
Capital invested by funds: $240M → $286M (+$45.4M)
0.01% more ownership
Funds ownership: 87.02% → 87.02% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
1% less funds holding
Funds holding: 90 → 89 (-1)
39% less call options, than puts
Call options by funds: $22K | Put options by funds: $36K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$1.19M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$1.03M |
| 3 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$777K |
| 4 |
BlackRock
New York
|
+$768K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$542K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.41M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$564K |
| 3 |
SC
Samlyn Capital
New York
|
-$474K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$287K |
| 5 |
Millennium Management
New York
|
-$226K |
INZY Hedge Fund Activity: Q3 2024 in Review
89 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q3 2024, worth a combined $286M — up 19% from $240M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of INZY and 10 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 37 added.
The largest buyer was Saturn V Capital Management, adding an estimated $1.19M. The largest seller was Sphera Funds Management, cutting an estimated $1.41M.
- 89 institutional investors held Inozyme Pharma (INZY) as of Q3 2024, down from 90 in Q2 2024.
- Funds reported $286M of Inozyme Pharma stock for Q3 2024, up 19% quarter-over-quarter.
- 10 funds opened new Inozyme Pharma positions in Q3 2024 and 11 closed out, a net change of -1 holder.
- The largest Inozyme Pharma buyer in Q3 2024 was Saturn V Capital Management, an estimated $1.19M added.
- The largest Inozyme Pharma seller in Q3 2024 was Sphera Funds Management, an estimated $1.41M sold.
Based on aggregated 13F filings for Q3 2024.